JP7606518B2 - 抗ｃｃｒ８抗体及びその使用 - Google Patents

抗ｃｃｒ８抗体及びその使用 Download PDF

Info

Publication number
JP7606518B2
JP7606518B2 JP2022535120A JP2022535120A JP7606518B2 JP 7606518 B2 JP7606518 B2 JP 7606518B2 JP 2022535120 A JP2022535120 A JP 2022535120A JP 2022535120 A JP2022535120 A JP 2022535120A JP 7606518 B2 JP7606518 B2 JP 7606518B2
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022535120A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023509323A (ja
JP2023509323A5 (https=
JPWO2021142002A5 (https=
Inventor
パメラ エム． ホランド，
アンドリュー レイク，
オースティン デュラク，
アーネスト スミス，
マリア スクリヴェンス，
キャリー ハービー，
レネ カーク，
レスリー バルチ，
ソニア ジー． ダス，
クリストファー コンバース ウェルズ，
Original Assignee
ヴァクシネックス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴァクシネックス， インコーポレイテッド filed Critical ヴァクシネックス， インコーポレイテッド
Publication of JP2023509323A publication Critical patent/JP2023509323A/ja
Publication of JP2023509323A5 publication Critical patent/JP2023509323A5/ja
Publication of JPWO2021142002A5 publication Critical patent/JPWO2021142002A5/ja
Priority to JP2024147372A priority Critical patent/JP7793001B2/ja
Application granted granted Critical
Publication of JP7606518B2 publication Critical patent/JP7606518B2/ja
Priority to JP2025154024A priority patent/JP2025178337A/ja
Priority to JP2025154025A priority patent/JP2025178338A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022535120A 2020-01-06 2021-01-06 抗ｃｃｒ８抗体及びその使用 Active JP7606518B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2024147372A JP7793001B2 (ja) 2020-01-06 2024-08-29 抗ｃｃｒ８抗体及びその使用
JP2025154024A JP2025178337A (ja) 2020-01-06 2025-09-17 抗ｃｃｒ８抗体及びその使用
JP2025154025A JP2025178338A (ja) 2020-01-06 2025-09-17 抗ｃｃｒ８抗体及びその使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062957758P 2020-01-06 2020-01-06
US62/957,758 2020-01-06
US202062985152P 2020-03-04 2020-03-04
US62/985,152 2020-03-04
US202063198803P 2020-11-13 2020-11-13
US63/198,803 2020-11-13
PCT/US2021/012329 WO2021142002A1 (en) 2020-01-06 2021-01-06 Anti-ccr8 antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024147372A Division JP7793001B2 (ja) 2020-01-06 2024-08-29 抗ｃｃｒ８抗体及びその使用

Publications (4)

Publication Number Publication Date
JP2023509323A JP2023509323A (ja) 2023-03-08
JP2023509323A5 JP2023509323A5 (https=) 2024-01-04
JPWO2021142002A5 JPWO2021142002A5 (https=) 2024-01-04
JP7606518B2 true JP7606518B2 (ja) 2024-12-25

Family

ID=74418541

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2022535120A Active JP7606518B2 (ja) 2020-01-06 2021-01-06 抗ｃｃｒ８抗体及びその使用
JP2024147372A Active JP7793001B2 (ja) 2020-01-06 2024-08-29 抗ｃｃｒ８抗体及びその使用
JP2025154024A Pending JP2025178337A (ja) 2020-01-06 2025-09-17 抗ｃｃｒ８抗体及びその使用
JP2025154025A Pending JP2025178338A (ja) 2020-01-06 2025-09-17 抗ｃｃｒ８抗体及びその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2024147372A Active JP7793001B2 (ja) 2020-01-06 2024-08-29 抗ｃｃｒ８抗体及びその使用
JP2025154024A Pending JP2025178337A (ja) 2020-01-06 2025-09-17 抗ｃｃｒ８抗体及びその使用
JP2025154025A Pending JP2025178338A (ja) 2020-01-06 2025-09-17 抗ｃｃｒ８抗体及びその使用

Country Status (12)

Country Link
US (3) US11859000B2 (https=)
EP (1) EP4087607A1 (https=)
JP (4) JP7606518B2 (https=)
KR (2) KR20250095745A (https=)
CN (1) CN114929278A (https=)
AR (1) AR132614A2 (https=)
AU (2) AU2021205877B2 (https=)
CA (1) CA3160204A1 (https=)
IL (2) IL321341A (https=)
MX (3) MX2022008341A (https=)
TW (2) TWI906906B (https=)
WO (1) WO2021142002A1 (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3616720B1 (en) * 2017-03-29 2021-02-17 Shionogi&Co., Ltd. Pharmaceutical composition for cancer treatment
KR20250095745A (ko) 2020-01-06 2025-06-26 백시넥스 인코포레이티드 항-ccr8 항체 및 이의 용도
WO2021155097A1 (en) * 2020-01-29 2021-08-05 The Wistar Institute Of Anatomy And Biology Cd40-l blockade to enhance synthetic antibody therapy
TW202216771A (zh) 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體
CN115052892B (zh) 2020-10-16 2023-07-07 礼新医药科技(上海)有限公司 抗ccr8单克隆抗体及其用途
CN117295820A (zh) 2021-03-31 2023-12-26 盐野义制药株式会社 以ccr8作为抗原识别的嵌合抗原受体
BR112023025433A2 (pt) 2021-06-04 2024-02-27 Amgen Inc Anticorpos anti-ccr8 e seus usos
EP4491635A3 (en) * 2021-07-27 2025-04-02 AbbVie Inc. Anti-ccr8 antibodies
WO2023020621A1 (en) * 2021-08-20 2023-02-23 Hifibio (Hk) Limited Anti-ccr8 antibodies and uses thereof
CN119930823A (zh) * 2021-12-23 2025-05-06 乐普创一生物科技（上海）有限公司 抗ccr8抗体及其应用
US20230279130A1 (en) * 2022-01-14 2023-09-07 Qilu Puget Sound Biotherapeutics Corporation Anti-ccr8 antibodies
CN116789820A (zh) * 2022-03-18 2023-09-22 北京天诺健成医药科技有限公司 一种新型免疫调节剂的开发和应用
WO2023206350A1 (en) * 2022-04-29 2023-11-02 Analytical Biosciences Shanghai Limited Anti-ccr8 antibodies and uses thereof
US20260028409A1 (en) 2022-05-24 2026-01-29 Bristol-Myers Squibb Company Antibodies that bind to human ccr8
EP4536278A2 (en) 2022-06-07 2025-04-16 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates
US20250388684A1 (en) * 2022-07-07 2025-12-25 Sichuan Swiftbio Biotechnology Co., Ltd Anti-ccr8 antibody and use thereofr
CA3263543A1 (en) * 2022-08-04 2024-02-08 Beone Medicines I Gmbh CCR8 ANTIBODIES AND METHODS OF USE
KR20250052418A (ko) * 2022-08-19 2025-04-18 피브로겐, 인크. 항-ccr8 항체 및 그의 용도
WO2024062072A2 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2024062082A1 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2024062076A1 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2024062019A1 (en) 2022-09-21 2024-03-28 Synabs Anti-ccr8 antibodies and uses thereof
EP4613766A1 (en) * 2022-11-04 2025-09-10 Biotheus Inc. Anti-ccr8 antibody and use thereof
CN120239710A (zh) * 2022-11-22 2025-07-01 上海宏成药业有限公司 抗ccr8抗体及其用途
WO2024120418A1 (zh) * 2022-12-07 2024-06-13 广东菲鹏制药股份有限公司 抗ccr8抗体及其应用
AR131786A1 (es) 2023-02-06 2025-04-30 Bayer Ag Combinación de anticuerpos ccr8 con inhibidores de dgk
WO2024240224A1 (zh) * 2023-05-23 2024-11-28 再鼎医药(上海)有限公司 包含抗ccr8抗体的制剂及其用途
JPWO2024248037A1 (https=) 2023-05-30 2024-12-05
EP4725967A1 (en) * 2023-06-12 2026-04-15 Nanjing Probio Biotech Co., Ltd. Antibody binding to human ccr8 and the use thereof
CN121152808A (zh) * 2023-06-16 2025-12-16 嘉和生物药业有限公司 抗ccr8抗体和抗ccr8/ctla4双特异性抗体
CN117285627B (zh) * 2023-09-06 2024-06-14 百济神州(上海)生物科技有限公司 抗ccr8抗体及其用途
EP4590714A1 (en) 2023-09-21 2025-07-30 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
EP4590715A1 (en) 2023-09-21 2025-07-30 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2025076288A1 (en) 2023-10-06 2025-04-10 Amgen Inc. Combination therapy for cancer treatment
AR134514A1 (es) 2023-12-01 2026-01-21 Gilead Sciences Inc Proteína de fusión anti-fap-ligera y uso de esta
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent
WO2025186043A1 (en) 2024-03-06 2025-09-12 Bayer Aktiengesellschaft Pharmaceutical formulation for anti-ccr8 antibodies
WO2025191147A1 (en) 2024-03-14 2025-09-18 Synabs Anti-ccr8 antibodies and uses thereof
WO2025226603A1 (en) 2024-04-22 2025-10-30 Surface Oncology, LLC Methods for treating cancer using anti-ccr8 antibodies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20260056209A1 (en) 2024-06-14 2026-02-26 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026017820A1 (en) * 2024-07-18 2026-01-22 Egle Therapeutics Fusion protein for cancer treatment
EP4681780A1 (en) * 2024-07-18 2026-01-21 Egle Therapeutics Immunocytokine for cancer treatment
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007044756A2 (en) 2005-10-11 2007-04-19 Icos Corporation Monoclonal antibodies recognizing human ccr8

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
EP0733070A1 (en) 1993-12-08 1996-09-25 Genzyme Corporation Process for generating specific antibodies
PT1231268E (pt) 1994-01-31 2005-11-30 Univ Boston Bancos de anticorpos policlonais
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US6001329A (en) 1996-05-06 1999-12-14 Uab Research Foundation Radiolabeled fusion toxins for cancer therapy
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
US6995259B1 (en) 1998-10-23 2006-02-07 Sirna Therapeutics, Inc. Method for the chemical synthesis of oligonucleotides
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP3263596A1 (en) 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulin variants and uses thereof
KR100891620B1 (ko) 2004-04-13 2009-04-02 에프. 호프만-라 로슈 아게 항-ｐ-셀렉틴 항체
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR20130108481A (ko) 2005-08-19 2013-10-02 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
WO2013131010A2 (en) 2012-03-02 2013-09-06 Icahn School Of Medicine At Mount Sinai Function of chemokine receptor ccr8 in melanoma metastasis
GB2519786A (en) 2013-10-30 2015-05-06 Sergej Michailovic Kiprijanov Multivalent antigen-binding protein molecules
BR112016015140A2 (pt) 2013-12-30 2018-01-23 Epimab Biotherapeutics Inc. imunoglobulina com fabs in-tandem e usos das mesmas
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
US10087259B1 (en) * 2014-04-28 2018-10-02 Memorial Sloan Kettering Cancer Center Depleting tumor-specific tregs
WO2018112033A1 (en) * 2016-12-13 2018-06-21 President And Fellows Of Harvard College Methods and compositions for targeting tumor-infiltrating tregs
EP3616720B1 (en) * 2017-03-29 2021-02-17 Shionogi&Co., Ltd. Pharmaceutical composition for cancer treatment
WO2019157098A1 (en) * 2018-02-06 2019-08-15 Advaxis, Inc. Compositions comprising a recombinant listeria strain and an anti-ccr8 antibody and methods of use
KR20250095745A (ko) 2020-01-06 2025-06-26 백시넥스 인코포레이티드 항-ccr8 항체 및 이의 용도

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007044756A2 (en) 2005-10-11 2007-04-19 Icos Corporation Monoclonal antibodies recognizing human ccr8

Also Published As

Publication number Publication date
US20210238292A1 (en) 2021-08-05
IL294330B2 (en) 2025-11-01
AU2021205877B2 (en) 2024-06-20
TW202136314A (zh) 2021-10-01
AU2024216306A1 (en) 2024-09-19
JP2023509323A (ja) 2023-03-08
JP2024170466A (ja) 2024-12-10
US12496342B2 (en) 2025-12-16
US11859000B2 (en) 2024-01-02
IL321341A (en) 2025-08-01
MX2024002158A (es) 2024-03-08
TW202438531A (zh) 2024-10-01
WO2021142002A1 (en) 2021-07-15
BR112022011749A2 (pt) 2022-08-30
CN114929278A (zh) 2022-08-19
MX2024002152A (es) 2024-03-08
AR132614A2 (es) 2025-07-16
TWI906906B (zh) 2025-12-01
CA3160204A1 (en) 2021-07-15
TWI845803B (zh) 2024-06-21
IL294330B1 (en) 2025-07-01
AU2021205877A1 (en) 2022-06-09
JP7793001B2 (ja) 2025-12-26
EP4087607A1 (en) 2022-11-16
JP2025178338A (ja) 2025-12-05
MX2022008341A (es) 2022-08-10
KR20220122628A (ko) 2022-09-02
JP2025178337A (ja) 2025-12-05
NZ788662A (en) 2024-11-29
IL294330A (en) 2022-08-01
US20240182588A1 (en) 2024-06-06
KR102821932B1 (ko) 2025-06-17
US20260091108A1 (en) 2026-04-02
KR20250095745A (ko) 2025-06-26

Similar Documents

Publication Publication Date Title
JP7793001B2 (ja) 抗ｃｃｒ８抗体及びその使用
JP7587858B2 (ja) ヒトｃｄ１３７に結合するアゴニスト性抗体およびその使用
JP2025011315A (ja) 抗ｉｌ－２７抗体及びその使用
US20210388089A1 (en) Antigen binding agents that bind cd277 and uses thereof
JP2024516970A (ja) 抗ｉｌ－２７抗体及びその使用
EA052697B1 (ru) Антитела против ccr8 и их применение
BR112022011749B1 (pt) Anticorpo ou porção de ligação ao antígeno do mesmo que se liga especificamente a um ou mais aminoácidos dentro do domínio n-terminal extracelular do ccr8 humano, anticorpo biespecífico ou multiespecífico, engajador de células t bispecífico (bite), anticorpo biparatópico, imunoconjugado e composição farmacêutica
BR122023027378B1 (pt) Uso de um anticorpo ou porção de ligação ao antígeno do mesmo que se liga especificamente a um ou mais aminoácidos dentro do domínio n-terminal extracelular do ccr8 humano e métodos in vitro para reduzir, causar depleção ou matar células t reguladoras infiltrantes de tumor e para ativar células nk ou induzir a morte mediada por células nk de células t reguladoras infiltrantes de tumor
BR122023027378A2 (pt) Uso de um anticorpo ou porção de ligação ao antígeno do mesmo que se liga especificamente a um ou mais aminoácidos dentro do domínio n-terminal extracelular do ccr8 humano, vetor e métodos para reduzir, causar depleção ou matar células t reguladoras infiltrantes de tumor e para ativar células nk ou induzir a morte mediada por células nk de células t reguladoras infiltrantes de tumor
WO2025226603A1 (en) Methods for treating cancer using anti-ccr8 antibodies
WO2020033925A9 (en) Antibodies that bind cd277 and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231221

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20231221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240418

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240829

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241126

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241213

R150 Certificate of patent or registration of utility model

Ref document number: 7606518

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150